KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Leases: 2019-2025

Historic Operating Leases for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Sep 2025 value amounting to $43.0 million.

  • Acadia Pharmaceuticals' Operating Leases rose 6.44% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year increase of 6.44%. This contributed to the annual value of $42.0 million for FY2024, which is 12.06% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Operating Leases of $43.0 million as of Q3 2025, which was down 3.53% from $44.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Operating Leases ranged from a high of $60.6 million in Q1 2021 and a low of $40.4 million during Q3 2024.
  • For the 3-year period, Acadia Pharmaceuticals' Operating Leases averaged around $46.2 million, with its median value being $47.2 million (2024).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Operating Leases spiked by 943.11% in 2021, and later decreased by 15.97% in 2024.
  • Acadia Pharmaceuticals' Operating Leases (Quarterly) stood at $56.1 million in 2021, then declined by 6.11% to $52.7 million in 2022, then decreased by 9.29% to $47.8 million in 2023, then declined by 12.06% to $42.0 million in 2024, then rose by 6.44% to $43.0 million in 2025.
  • Its last three reported values are $43.0 million in Q3 2025, $44.6 million for Q2 2025, and $44.6 million during Q1 2025.